Click Therapeutics Secures $30 Million In Growth Capital From K2 HealthVentures
Click Therapeutics, Inc. secured $30 million in growth capital from K2 HealthVentures to accelerate commercialization of its digital smoking cessation solution, Clickotine. Click develops and markets prescription digital medical treatments; some of the growth capital will be used to advance its pipeline.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes . . .